BIOMAT Database Logo BIOMAT Database Logo

[Plasma levels following the switch from amprenavir to fosamprenavir in HIV-infected patients under antiretroviral treatment with lopinavir/ritonavir]. 2008

Olga Delgado, and Melchor Riera, and Javier Murillas, and Pere Ventayol

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010755 Organophosphates Carbon-containing phosphoric acid derivatives. Included under this heading are compounds that have CARBON atoms bound to one or more OXYGEN atoms of the P( Organophosphate,Phosphates, Organic,Phosphoric Acid Esters,Organopyrophosphates,Acid Esters, Phosphoric,Esters, Phosphoric Acid,Organic Phosphates
D011744 Pyrimidinones Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O. Pyrimidinone,Pyrimidone,Pyrimidones
D002219 Carbamates Derivatives of carbamic acid, H2NC( Carbamate,Aminoformic Acids,Carbamic Acids,Acids, Aminoformic,Acids, Carbamic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005663 Furans Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. Tetrahydrofurans
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Olga Delgado, and Melchor Riera, and Javier Murillas, and Pere Ventayol
Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
January 2007, Antiviral therapy,
Olga Delgado, and Melchor Riera, and Javier Murillas, and Pere Ventayol
Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
October 2007, The Journal of antimicrobial chemotherapy,
Olga Delgado, and Melchor Riera, and Javier Murillas, and Pere Ventayol
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
January 2005, AIDS (London, England),
Olga Delgado, and Melchor Riera, and Javier Murillas, and Pere Ventayol
Effect of reduced-dose amprenavir in combination with lopinavir on plasma levels of amprenavir in patients infected with HIV.
March 2001, Clinical therapeutics,
Olga Delgado, and Melchor Riera, and Javier Murillas, and Pere Ventayol
Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.
February 2014, Journal of clinical pharmacology,
Olga Delgado, and Melchor Riera, and Javier Murillas, and Pere Ventayol
Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
June 2009, AIDS (London, England),
Olga Delgado, and Melchor Riera, and Javier Murillas, and Pere Ventayol
Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.
August 2008, International journal of STD & AIDS,
Olga Delgado, and Melchor Riera, and Javier Murillas, and Pere Ventayol
Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families.
January 2002, HIV clinical trials,
Olga Delgado, and Melchor Riera, and Javier Murillas, and Pere Ventayol
Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patients.
August 2013, Antimicrobial agents and chemotherapy,
Olga Delgado, and Melchor Riera, and Javier Murillas, and Pere Ventayol
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients.
January 2004, AIDS (London, England),
Copied contents to your clipboard!